With the growing volume of biosimilar and pharma litigation in district courts and before the PTAB, the U.S. International Trade Commission may emerge as another forum for patent holders against imported biosimilars. Section 337 of the Tariff Act of 1930 allows patent holders with a domestic industry relating to the…
